We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes (Lilly ITSZ)
Principal Investigator: Richard Bergenstal, MD
Study Sponsor: Eli Lilly and Company
Location: International Diabetes Center
Phase of Study: Phase 2
Purpose of study: This study will look at how much time participants’ blood sugars are in target ranges while using LY900014 (Lyumjev), which is an ultra-rapid acting version of insulin Humalog (lispro) for meal-time insulin, along with long acting insulin Tresiba (degludec). Insulin will be provided during the study. Participants will be using some of the latest technologies such as a continuous glucose monitor (CGM), a smart insulin pen injector and phone apps, to track blood sugars for themselves and to provide this information to the study doctor. A new strategy to adjust insulin will be used to improve participants’ blood sugars.
Inclusion Criteria:
The study is accepting individuals ages 18-65 who:
• Have had type 1 diabetes for at least 1 year
• Use insulin injections (not an insulin pump)
• Have been using a Dexcom G5 or G6 CGM
• Are willing to use the Dexcom G6 CGM provided by the study
• Meet other study specific criteria
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@parknicollet.com
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients (inRange)
Principal Investigator: Richard Bergenstal, MD
Study Sponsor: Sanofi
Location: International Diabetes Center
Purpose of study: This study will compare how two different FDA approved long acting insulins work for people with type 1 diabetes. Participants will be provided with either insulin Tuojeo and Tresiba throughout the study to take in addition to their rapid acting insulin. Continuous glucose monitoring (CGM) will be used to measure glucose levels.
Inclusion Criteria: The study is accepting males and females ages 18-70 who:
• Have type 1 diabetes
• Take multiple daily insulin injections for their diabetes
• Have an A1C between 7.0-10.0%
• Meet other study specific requirements
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@parknicollet.com
Evaluating the Safety and Effectiveness of the Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes
Principal Investigator: Anders Carlson, MD
Study Sponsor: Insulet Corporation
Location: International Diabetes Center
Purpose of study: This study will be testing a new insulin delivery system in people who have type 2 diabetes. The system is called the Omnipod 5 Automated Insulin Delivery System. The study is being done to find out how well the insulin pump system works to automatically infuse insulin for control of glucose levels in people with type 2 diabetes. The system consists of a tubeless insulin pump (pod), the Omnipod 5 Controller, and the Dexcom G6 Continuous Glucose Monitoring System® (CGM). Omnipod 5 Automated Insulin Delivery System is provided for use during the study, including related supplies, at no cost to you. Glucose meter and strips used during the study are provided at no cost to you.
Inclusion Criteria:
The study is accepting individuals ages 18-75 who:
• Have type 2 diabetes and are using insulin
• Have an A1C 8-12%
• Are willing to use the insulin pump system throughout the study
• Meet other study specific criteria
Study Contact:
Caitlin Hasledalen
(952) 993-9605
IDCResearch@parknicollet.com
